Drug interaction classified as: metabolism
Source: DDInter
BCL2 inhibitor (BH3 mimetic) · Antineoplastic agent
Venetoclax is a first-in-class, orally bioavailable, small-molecule inhibitor of BCL2. It was designed as a BH3 mimetic that inhibits BCL2 interaction with the proapoptotic BH3-only family members, such as BIM, BID, and BAD. In the presence of venetoclax, BH3-only proteins can translocate to mitochondria and initiate BAX/BAK-dependent apoptosis. It helps restore apoptosis in CLL cells.
D
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: absorption
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Increased venetoclax exposure.
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: absorption
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team